Panacea Biotec Q3 FY26: standalone loss Rs 7.4 cr, 9M revenue up 25%

Revenue growth above 20%Net loss reportedExceptional itemGoing-concern doubtResults View source PDF Explain this filing

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹351.90

prior close

₹359.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+2.2% vs market

Pharmaceuticals peers, median of 157sector-0.7%+2.3% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.5

15m

-1.1

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.7-0.5+2.2-0.7+2.3

Next day

-1.5-2.0+0.5-1.4-0.1

-1.4-2.7+1.3-2.1+0.7

+2.0-1.7+3.7-1.6+3.7

-0.3-1.4+1.1-1.6+1.3

-1.8-2.8+1.0-2.5+0.6

-3.7-2.8-0.9-2.9-0.8

15d

-9.2-8.4-0.8-6.3-2.9

-2.8-9.1+6.3-6.6+3.8

-5.5-4.0-1.5-3.3-2.2

+4.4+2.6+1.8+0.7+3.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Panacea Biotec reported Q3 FY26 (Oct-Dec 2025) standalone revenue of Rs 99.3 crore vs Rs 108.4 crore YoY and consolidated revenue of Rs 165.2 crore vs Rs 163.5 crore. Standalone net loss was Rs 7.4 crore versus profit of Rs 9.7 crore YoY. 9M FY26 standalone revenue grew 25 percent to Rs 302.4 crore, but loss widened to Rs 29.7 crore from Rs 2.8 crore. Consolidated 9M loss narrowed to Rs 6.2 crore. Exceptional income of Rs 16.8 crore includes an Rs 8.6 crore Apotex settlement. Vaccines segment drove growth.

Likely market impact

Mixed: revenue growth but standalone losses persist. Exceptional items support consolidated profit. Management maintains going concern with new vaccine orders.